{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:15:52Z","timestamp":1788509752093,"version":"build-2803163510"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02407-y","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:46:43Z","timestamp":1788508003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication"],"prefix":"10.1007","volume":"28","author":[{"given":"Jean","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraaz","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Arbune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad G.","family":"Zaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-1644","authenticated-orcid":false,"given":"Alvin","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2407_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, Cheng RK, Kittleson MM, Upshaw JN, Palaskas N, et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. J Card Fail. 2025;31:415\u201355. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045.","journal-title":"J Card Fail"},{"key":"2407_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966\u201383. https:\/\/doi.org\/10.1002\/ejhf.2017.","journal-title":"Eur J Heart Fail"},{"key":"2407_CR3","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1161\/CIR.0000000000001032","volume":"144","author":"VG Zaha","year":"2021","unstructured":"Zaha VG, Hayek SS, Alexander KM, Beckie TM, Hundley WG, Kondapalli L, Ky B, Leger KJ, Meijers WC, Moslehi JJ, Shah SH. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation. 2021;144:e551\u201363. https:\/\/doi.org\/10.1161\/CIR.0000000000001032.","journal-title":"Circulation"},{"key":"2407_CR4","doi-asserted-by":"publisher","first-page":"e70057","DOI":"10.1002\/cam4.70057","volume":"13","author":"HS Ng","year":"2024","unstructured":"Ng HS, Meng R, Marin TS, Damarell RA, Buckley E, Selvanayagam JB, Koczwara B. Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis. Cancer Med. 2024;13:e70057. https:\/\/doi.org\/10.1002\/cam4.70057.","journal-title":"Cancer Med"},{"key":"2407_CR5","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u201397. https:\/\/doi.org\/10.1093\/eurheartj\/ehz766.","journal-title":"Eur Heart J"},{"key":"2407_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","volume":"80","author":"R Florido","year":"2022","unstructured":"Florido R, Daya NR, Ndumele CE, Koton S, Russell SD, Prizment A, Blumenthal RS, Matsushita K, Mok Y, Felix AS, et al. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022;80:22\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.042.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400.","journal-title":"J Clin Oncol"},{"key":"2407_CR8","doi-asserted-by":"publisher","first-page":"e926","DOI":"10.1161\/CIR.0000000000001308","volume":"151","author":"TD Ryan","year":"2025","unstructured":"Ryan TD, Bates JE, Kinahan KE, Leger KJ, Mulrooney DA, Narayan HK, Ness K, Okwuosa TM, Rainusso NC, Steinberger J, et al. Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. Circulation. 2025;151:e926\u201343. https:\/\/doi.org\/10.1161\/CIR.0000000000001308.","journal-title":"Circulation"},{"key":"2407_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, Totzeck M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22:350\u201361. https:\/\/doi.org\/10.1002\/ejhf.1631.","journal-title":"Eur J Heart Fail"},{"key":"2407_CR10","doi-asserted-by":"publisher","first-page":"e000097","DOI":"10.1161\/HCG.0000000000000097","volume":"18","author":"R Khera","year":"2025","unstructured":"Khera R, Asnani AH, Krive J, Addison D, Zhu H, Vasbinder A, Fleming MR, Arnaout R, Razavi P, Okwuosa TM, et al. Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2025;18:e000097. https:\/\/doi.org\/10.1161\/HCG.0000000000000097.","journal-title":"Circ Genom Precis Med"},{"key":"2407_CR11","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","volume":"77","author":"VU Rao","year":"2021","unstructured":"Rao VU, Reeves DJ, Chugh AR, O\u2019Quinn R, Fradley MG, Raghavendra M, Dent S, Barac A, Lenihan D. Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77:2693\u2013716. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.009.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR12","doi-asserted-by":"publisher","first-page":"102022","DOI":"10.1016\/j.jacadv.2025.102022","volume":"4","author":"C Mann","year":"2025","unstructured":"Mann C, Pailer U, Spannbauer A, Hamidi F, Braser AV, Hulsmann M, Gerges C, Gottsauner-Wolf M, Gyongyosi M, Raderer M, et al. Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy. JACC Adv. 2025;4:102022. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102022.","journal-title":"JACC Adv"},{"key":"2407_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/10815589251382263","volume":"74","author":"C Aura","year":"2026","unstructured":"Aura C, Salcedo L, Loayza Pintado J, Matos C, Mogollon I, Arias F, Cobos E. Silent damage, early signals: A narrative review of the evolving role of cardiac biomarkers in oncology-driven cardiotoxicity. J Investig Med. 2026;74:299\u2013308. https:\/\/doi.org\/10.1177\/10815589251382263.","journal-title":"J Investig Med"},{"key":"2407_CR14","doi-asserted-by":"publisher","unstructured":"Semeraro GC, Cipolla CM, Cardinale DM. Role of Cardiac Biomarkers in Cancer Patients. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13215426.","DOI":"10.3390\/cancers13215426"},{"key":"2407_CR15","doi-asserted-by":"publisher","first-page":"e029574","DOI":"10.1161\/JAHA.123.029574","volume":"12","author":"G Murtagh","year":"2023","unstructured":"Murtagh G, Januzzi JL, Scherrer-Crosbie M, Neilan TG, Dent S, Ho JE, Appadurai V, McDermott R, Akhter N. Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions. J Am Heart Assoc. 2023;12:e029574. https:\/\/doi.org\/10.1161\/JAHA.123.029574.","journal-title":"J Am Heart Assoc"},{"key":"2407_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2024.12.003","volume":"399","author":"J Song","year":"2026","unstructured":"Song J, Liu S, Shi X, Gao J, Spanos M, Zhou Q, Xiao J. Biomarkers for cancer therapy-related cardiovascular toxicity. Int Rev Cell Mol Biol. 2026;399:1\u201342. https:\/\/doi.org\/10.1016\/bs.ircmb.2024.12.003.","journal-title":"Int Rev Cell Mol Biol"},{"key":"2407_CR17","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.jacc.2020.03.067","volume":"75","author":"V Narayan","year":"2020","unstructured":"Narayan V, Thompson EW, Demissei B, Ho JE, Januzzi JL Jr., Ky B. Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:2726\u201337. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.067.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jacc.2018.12.046","volume":"73","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr., Mahler SA, Christenson RH, Rymer J, Newby LK, Body R, Morrow DA, Jaffe AS. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73:1059\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.046.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR19","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1001\/jama.2013.5809","volume":"309","author":"JA de Lemos","year":"2013","unstructured":"de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013;309:2262\u20139. https:\/\/doi.org\/10.1001\/jama.2013.5809.","journal-title":"JAMA"},{"key":"2407_CR20","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Executive Group on behalf of the Joint European Society of Cardiology \/American College of Cardiology \/American Heart Association \/World Heart Federation Task Force for the Universal Definition of Myocardial I. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72:2231\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1038.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jacc.2017.07.718","volume":"70","author":"R Twerenbold","year":"2017","unstructured":"Twerenbold R, Boeddinghaus J, Nestelberger T, Wildi K, Rubini Gimenez M, Badertscher P, Mueller C. Clinical Use of High-Sensitivity Cardiac Troponin in Patients With Suspected Myocardial Infarction. J Am Coll Cardiol. 2017;70:996\u20131012. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.718.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamacardio.2019.2724","volume":"4","author":"CP McCarthy","year":"2019","unstructured":"McCarthy CP, Raber I, Chapman AR, Sandoval Y, Apple FS, Mills NL, Januzzi JL. Jr. Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians. JAMA Cardiol. 2019;4:1034\u201342. https:\/\/doi.org\/10.1001\/jamacardio.2019.2724.","journal-title":"JAMA Cardiol"},{"key":"2407_CR23","doi-asserted-by":"publisher","first-page":"20453","DOI":"10.1002\/jcp.28647","volume":"234","author":"M Buoncervello","year":"2019","unstructured":"Buoncervello M, Maccari S, Ascione B, Gambardella L, Marconi M, Spada M, Macchia D, Stati T, Patrizio M, Malorni W, et al. Inflammatory cytokines associated with cancer growth induce mitochondria and cytoskeleton alterations in cardiomyocytes. J Cell Physiol. 2019;234:20453\u201368. https:\/\/doi.org\/10.1002\/jcp.28647.","journal-title":"J Cell Physiol"},{"key":"2407_CR24","doi-asserted-by":"publisher","first-page":"2049487","DOI":"10.1080\/2162402x.2022.2049487","volume":"11","author":"J Cedervall","year":"2022","unstructured":"Cedervall J, Herre M, Dragomir A, Rabelo-Melo F, Svensson A, Th\u00e5lin C, Rosell A, Hjalmar V, Wall\u00e9n H, Lindman H, et al. Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress. Oncoimmunology. 2022;11:2049487. https:\/\/doi.org\/10.1080\/2162402x.2022.2049487.","journal-title":"Oncoimmunology"},{"key":"2407_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jacc.2025.10.018","volume":"87","author":"S Ganatra","year":"2026","unstructured":"Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF, Hayek S, Ky B, Leja M, Lucas CH, et al. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton\u2019s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2026;87:654\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2025.10.018.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR26","doi-asserted-by":"publisher","unstructured":"Gulati G, Heck SL, Rosjo H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. J Am Heart Assoc. 2017;6. https:\/\/doi.org\/10.1161\/JAHA.117.006513.","DOI":"10.1161\/JAHA.117.006513"},{"key":"2407_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","volume":"12","author":"J Herrmann","year":"2026","unstructured":"Herrmann J, Barac A, Carver J, Cheng RK, Daniele A, Dent S, Deych E, Lee DH, Lenihan D, Leong DP, et al. Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement. JAMA Oncol. 2026;12:90\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2025.4543.","journal-title":"JAMA Oncol"},{"key":"2407_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/circulationaha.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, Stein F, Bretagne M, Ederhy S, Fenioux C, et al. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis. Circulation. 2023;148:473\u201386. https:\/\/doi.org\/10.1161\/circulationaha.123.062405.","journal-title":"Circulation"},{"key":"2407_CR29","doi-asserted-by":"publisher","first-page":"115186","DOI":"10.1016\/j.ejca.2024.115186","volume":"216","author":"D Tomsitz","year":"2025","unstructured":"Tomsitz D, Grabmaier U, Spiro J, Nicolai L, French LE, Massberg S, Heinzerling L. Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T. Eur J Cancer. 2025;216:115186. https:\/\/doi.org\/10.1016\/j.ejca.2024.115186.","journal-title":"Eur J Cancer"},{"key":"2407_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jaccao.2023.03.015","volume":"5","author":"PF van den Berg","year":"2023","unstructured":"van den Berg PF, Aboumsallem JP, Screever EM, Shi C, de Wit S, Bracun V, Yousif LI, Geerlings L, Wang D, Ho JE, et al. Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure. JACC CardioOncol. 2023;5:445\u201353. https:\/\/doi.org\/10.1016\/j.jaccao.2023.03.015.","journal-title":"JACC CardioOncol"},{"key":"2407_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejim.2022.01.012","volume":"98","author":"A Aimo","year":"2022","unstructured":"Aimo A, Georgiopoulos G, Panichella G, Vergaro G, Passino C, Emdin M, Clerico A. High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. Eur J Intern Med. 2022;98:61\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2022.01.012.","journal-title":"Eur J Intern Med"},{"key":"2407_CR32","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/eurheartj\/ehad328","volume":"44","author":"JW McEvoy","year":"2023","unstructured":"McEvoy JW, Daya N, Tang O, Fang M, Ndumele CE, Coresh J, Christenson RH, Selvin E. High-sensitivity troponins and mortality in the general population. Eur Heart J. 2023;44:2595\u2013605. https:\/\/doi.org\/10.1093\/eurheartj\/ehad328.","journal-title":"Eur Heart J"},{"key":"2407_CR33","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jacc.2021.01.011","volume":"77","author":"I Raber","year":"2021","unstructured":"Raber I, McCarthy CP, Januzzi JL. Jr. A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings. J Am Coll Cardiol. 2021;77:1357\u201367. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.011.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jacc.2017.05.062","volume":"70","author":"P Willeit","year":"2017","unstructured":"Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, Ford I, Trompet S, Stott DJ, Kearney PM, et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. J Am Coll Cardiol. 2017;70:558\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.062.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/eurjpc\/zwae116","volume":"33","author":"H Bashar","year":"2026","unstructured":"Bashar H, Kobo O, Curzen N, Mamas MA. Association of myocardial injury with adverse long-term survival among cancer patients. Eur J Prev Cardiol. 2026;33:548\u201356. https:\/\/doi.org\/10.1093\/eurjpc\/zwae116.","journal-title":"Eur J Prev Cardiol"},{"key":"2407_CR36","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/clc.23486","volume":"43","author":"SH Park","year":"2020","unstructured":"Park SH, Kim T, Cha WC, Yoon H, Hwang SY, Shin TG, Sim MS, Jo I, Lee SH, Park HD, Choi JH. Cardiac troponin I predicts clinical outcome of patients with cancer at emergency department. Clin Cardiol. 2020;43:1585\u201391. https:\/\/doi.org\/10.1002\/clc.23486.","journal-title":"Clin Cardiol"},{"key":"2407_CR37","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","volume":"101","author":"N Pavo","year":"2015","unstructured":"Pavo N, Raderer M, H\u00fclsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874\u201380. https:\/\/doi.org\/10.1136\/heartjnl-2015-307848.","journal-title":"Heart"},{"key":"2407_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40959-024-00238-w","volume":"10","author":"NA Samuel","year":"2024","unstructured":"Samuel NA, Roddick A, Glampson B, Mulla A, Davies J, Papadimitriou D, Panoulas V, Mayer E, Woods K, Shah AD, et al. Prognostic significance of troponin in patients with malignancy (NIHR Health Informatics Collaborative TROP-MALIGNANCY study). Cardiooncology. 2024;10:41. https:\/\/doi.org\/10.1186\/s40959-024-00238-w.","journal-title":"Cardiooncology"},{"key":"2407_CR39","doi-asserted-by":"publisher","unstructured":"Kozhukhov S, Dovganych N. The Prognostic Value of High-Sensitive Troponin T Rise Within the Upper Reference Limit in Breast Cancer: A Prospective Pilot Study. Cancers (Basel). 2025;17. https:\/\/doi.org\/10.3390\/cancers17142412.","DOI":"10.3390\/cancers17142412"},{"key":"2407_CR40","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ijrobp.2021.07.035","volume":"111","author":"T Xu","year":"2021","unstructured":"Xu T, Meng QH, Gilchrist SC, Lin SH, Lin R, Xu T, Milgrom SA, Gandhi SJ, Wu H, Zhao Y, et al. Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys. 2021;111:907\u201316. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.035.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2407_CR41","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, R\u00f8sj\u00f8 H, Steine K, Geisler J, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2\u00d72 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021;143:2431\u201340. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054698.","journal-title":"Circulation"},{"key":"2407_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaccao.2023.10.008","volume":"6","author":"A Mecinaj","year":"2024","unstructured":"Mecinaj A, Gulati G, Ree AH, Gravdehaug B, R\u00f8sj\u00f8 H, Steine K, Wisl\u00f8ff T, Geisler J, Omland T, Heck SL. Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction. JACC CardioOncol. 2024;6:83\u201395. https:\/\/doi.org\/10.1016\/j.jaccao.2023.10.008.","journal-title":"JACC CardioOncol"},{"key":"2407_CR43","doi-asserted-by":"publisher","unstructured":"Lin N, Xie L, An L, Wei G. Cardiac Troponin I for Early Detection of Cancer Therapy-Related Cardiac Dysfunction after Chemotherapy: A Diagnostic Test Accuracy Meta-Analysis. Cardiology. 2025;1\u201316. https:\/\/doi.org\/10.1159\/000549271.","DOI":"10.1159\/000549271"},{"key":"2407_CR44","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lewis S, Rodriguez A, Fletcher A, Everett RJ, et al. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I\u2013Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Circulation. 2023;148:1680\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064274.","journal-title":"Circulation"},{"key":"2407_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaccao.2025.06.003","volume":"7","author":"K Loganath","year":"2025","unstructured":"Loganath K, Lee KK, Oikonomidou O, Hall P, Mills NL, Joshi S, Singh T, McGillivray T, Semple S, Lang NN, et al. Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial. JACC: CardioOncology. 2025;7:725\u201335. https:\/\/doi.org\/10.1016\/j.jaccao.2025.06.003.","journal-title":"JACC: CardioOncology"},{"key":"2407_CR46","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/circulationaha.125.073322","volume":"152","author":"MG Bonatto","year":"2025","unstructured":"Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres RA, Costa AN, Costa N, Coiradas AO, Mialski TBR, Maiolino J, et al. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Circulation. 2025;152:1742\u201355. https:\/\/doi.org\/10.1161\/circulationaha.125.073322.","journal-title":"Circulation"},{"key":"2407_CR47","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jacc.2025.12.029","volume":"87","author":"J Butler","year":"2026","unstructured":"Butler J, Khan MS, Ferreira JP, Girerd N, Gulati M, Lala A, Petrie MC, Stockbridge N, Vaduganathan M, Zannad F. Heart Failure Prevention: Evidence Generation, Trial Design, and Regulatory Pathways. J Am Coll Cardiol. 2026;87:1907\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2025.12.029.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR48","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/circulationaha.125.076616","volume":"152","author":"T Omland","year":"2025","unstructured":"Omland T, Heck SL, Holte E, Lilleaasen AM, Gynnild MN, Fagerland MW, Vinje-Jakobsen V, N\u00e6s AL, Blix ES, Larsen AI, et al. Sacubitril\/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation. 2025;152:1136\u201345. https:\/\/doi.org\/10.1161\/circulationaha.125.076616.","journal-title":"Circulation"},{"key":"2407_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.amjcard.2026.03.068","volume":"269","author":"R Huntermann","year":"2026","unstructured":"Huntermann R, Molinari ME, Batista PG, de Oliveira JP, Muniz J, de Lucena LA, Sato MY, Melo ES, Giorgi J, Bacca CdOF. Sacubitril\/Valsartan and Prevention of Chemotherapy-Induced Cardiac Dysfunction: Meta-analysis of Randomized Trials. Am J Cardiol. 2026;269:83\u201391. https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.068.","journal-title":"Am J Cardiol"},{"key":"2407_CR50","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/jco.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910\u20136. https:\/\/doi.org\/10.1200\/jco.2009.27.3615.","journal-title":"J Clin Oncol"},{"key":"2407_CR51","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/jco.2015.65.7916","volume":"35","author":"D Zardavas","year":"2017","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, Al-Sakaff N, Piccart-Gebhart MJ, de Azambuja E. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. J Clin Oncol. 2017;35:878\u201384. https:\/\/doi.org\/10.1200\/jco.2015.65.7916.","journal-title":"J Clin Oncol"},{"key":"2407_CR52","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/cir.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018;137:e30\u201366. https:\/\/doi.org\/10.1161\/cir.0000000000000556.","journal-title":"Circulation"},{"key":"2407_CR53","doi-asserted-by":"publisher","unstructured":"Gvili Perelman M, Brzezinski RY, Waissengrin B, Leshem Y, Raphael A, Perelman M, Weiss N, Tzuberi M, Stark M, Goldiner I, et al. The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors. Oncologist. 2025;30. https:\/\/doi.org\/10.1093\/oncolo\/oyaf147.","DOI":"10.1093\/oncolo\/oyaf147"},{"key":"2407_CR54","doi-asserted-by":"publisher","first-page":"e041680","DOI":"10.1161\/jaha.125.041680","volume":"15","author":"M Pereyra Pietri","year":"2026","unstructured":"Pereyra Pietri M, Farina JM, Awad K, Kanaan CN, Scalia IG, Tagle-Cornell C, Novais BS, Koepke LM, Kenyon CR, Mahmoud AK, et al. Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. J Am Heart Assoc. 2026;15:e041680. https:\/\/doi.org\/10.1161\/jaha.125.041680.","journal-title":"J Am Heart Assoc"},{"key":"2407_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00392-022-02118-8","volume":"112","author":"B Waissengein","year":"2023","unstructured":"Waissengein B, Abu Ata B, Merimsky O, Shamai S, Wolf I, Arnold JH, Bar-On T, Banai S, Khoury S, Laufer-Perl M. The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors. Clin Res Cardiol. 2023;112:409\u201318. https:\/\/doi.org\/10.1007\/s00392-022-02118-8.","journal-title":"Clin Res Cardiol"},{"key":"2407_CR56","doi-asserted-by":"publisher","first-page":"101375","DOI":"10.1016\/j.jacadv.2024.101375","volume":"3","author":"PF van den Berg","year":"2024","unstructured":"van den Berg PF, Bracun V, Noordman M, van der Meer P, Shi C, Oosting SF, Aboumsallem JP, de Wit S, Meijers WC, Jalving M, et al. Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective Study. JACC Adv. 2024;3:101375. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101375.","journal-title":"JACC Adv"},{"key":"2407_CR57","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073\u2013126. https:\/\/doi.org\/10.1200\/jco.21.01440.","journal-title":"J Clin Oncol"},{"key":"2407_CR58","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"2407_CR59","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaccao.2025.01.020","volume":"7","author":"YC Chen","year":"2025","unstructured":"Chen YC, Dolladille C, Rao A, Palaskas NL, Deswal A, Lehmann L, Cautela J, Courand PY, Hayek S, Zhu H, et al. Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction. JACC CardioOncol. 2025;7:234\u201348. https:\/\/doi.org\/10.1016\/j.jaccao.2025.01.020.","journal-title":"JACC CardioOncol"},{"key":"2407_CR60","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","volume":"5","author":"O Itzhaki Ben Zadok","year":"2023","unstructured":"Itzhaki Ben Zadok O, Levi A, Divakaran S, Nohria A. Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis: Contemporary 1-Year Outcomes. JACC CardioOncol. 2023;5:732\u201344. https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.004.","journal-title":"JACC CardioOncol"},{"key":"2407_CR61","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, et al. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019;74:3099\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.038.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR62","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","volume":"43","author":"M Totzeck","year":"2022","unstructured":"Totzeck M, Michel L, Lin Y, Herrmann J, Rassaf T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022;43:1928\u201340. https:\/\/doi.org\/10.1093\/eurheartj\/ehac106.","journal-title":"Eur Heart J"},{"key":"2407_CR63","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","volume":"44","author":"SS Mahmood","year":"2023","unstructured":"Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Rehman M, Mead E, Liu JE, Devereux RB, et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023;44:2029\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehad117.","journal-title":"Eur Heart J"},{"key":"2407_CR64","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","volume":"74","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C, Mousavi N, Park JH, Perales MA, et al. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. J Am Coll Cardiol. 2019;74:3153\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.049.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR65","unstructured":"National Comprehensive Cancer Network. Management of CAR T-Cell and Lymphocyte Engager-Related Toxicities vNCPGiOPN, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cellular_tox.pdf?utm_source=openevidence"},{"key":"2407_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.59249\/NCST6937","volume":"96","author":"M Samad","year":"2023","unstructured":"Samad M, Malempati S, Restini CBA. Natriuretic Peptides as Biomarkers: Narrative Review and Considerations in Cardiovascular and Respiratory Dysfunctions. Yale J Biol Med. 2023;96:137\u201349. https:\/\/doi.org\/10.59249\/NCST6937.","journal-title":"Yale J Biol Med"},{"key":"2407_CR67","doi-asserted-by":"publisher","first-page":"e2546201","DOI":"10.1001\/jamanetworkopen.2025.46201","volume":"8","author":"C Xia","year":"2025","unstructured":"Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, Zhang L, Liu PP, Landsburg D, Clark AS, et al. Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical Trial. JAMA Netw Open. 2025;8:e2546201. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.46201.","journal-title":"JAMA Netw Open"},{"key":"2407_CR68","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ejhf.3497","volume":"27","author":"MS Anker","year":"2025","unstructured":"Anker MS, Luck LC, Khan MS, Porthun J, Hadzibegovic S, Lena A, Wilkenshoff U, Weinlander P, Evertz R, Totzeck M, et al. New cardiovascular biomarkers in patients with advanced cancer - A prospective study comparing MR-proADM, MR-proANP, copeptin, high-sensitivity troponin T and NT-proBNP. Eur J Heart Fail. 2025;27:1047\u201355. https:\/\/doi.org\/10.1002\/ejhf.3497.","journal-title":"Eur J Heart Fail"},{"key":"2407_CR69","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1016\/j.jtha.2024.07.019","volume":"22","author":"S Kraler","year":"2024","unstructured":"Kraler S, Liberale L, Nopp S, Englisch C, Grilz E, Lapikova-Bryhinska T, Akhmedov A, Carbone F, Ramoni D, Tirandi A, et al. Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study. J Thromb Haemost. 2024;22:3125\u201336. https:\/\/doi.org\/10.1016\/j.jtha.2024.07.019.","journal-title":"J Thromb Haemost"},{"key":"2407_CR70","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s12012-022-09755-5","volume":"22","author":"ZY Liu","year":"2022","unstructured":"Liu ZY, Wang YG, Huang XB, Qi XH, Qian CP, Zhao S. Development and Validation of a Diagnostic Nomogram to Predict the Anthracycline-Induced Early Cardiotoxicity in Children with Hematological Tumors. Cardiovasc Toxicol. 2022;22:802\u201312. https:\/\/doi.org\/10.1007\/s12012-022-09755-5.","journal-title":"Cardiovasc Toxicol"},{"key":"2407_CR71","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1097\/MJT.0000000000000930","volume":"27","author":"A Bisoc","year":"2020","unstructured":"Bisoc A, Ciurescu D, Radoi M, Tantu MM, Rogozea L, Sweidan AJ, Bota DA. Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy. Am J Ther. 2020;27:e142\u201350. https:\/\/doi.org\/10.1097\/MJT.0000000000000930.","journal-title":"Am J Ther"},{"key":"2407_CR72","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017;70:2536\u201351. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1096.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR73","doi-asserted-by":"publisher","first-page":"e20020","DOI":"10.7717\/peerj.20020","volume":"13","author":"C He","year":"2025","unstructured":"He C, Xu L, Zhang Z, Wang J. NT-proBNP serves as a prognostic marker for adverse outcomes in severe immune checkpoint inhibitor-associated myocarditis. PeerJ. 2025;13:e20020. https:\/\/doi.org\/10.7717\/peerj.20020.","journal-title":"PeerJ"},{"key":"2407_CR74","doi-asserted-by":"publisher","first-page":"e038719","DOI":"10.1161\/JAHA.124.038719","volume":"14","author":"N Dubey","year":"2025","unstructured":"Dubey N, Wu CY, Zubiri L, Fay M, Rouhani SJ, Merkin RD, Sun J, Locascio JJ, Neilan TG, Reynolds KL, Zlotoff DA. Predictors of Long-Term Survival in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2025;14:e038719. https:\/\/doi.org\/10.1161\/JAHA.124.038719.","journal-title":"J Am Heart Assoc"},{"key":"2407_CR75","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","volume":"25","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, Chioncel O, Defilippi CR, Drazner MH, Felker GM, et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Eur J Heart Fail. 2023;25:616\u201331. https:\/\/doi.org\/10.1002\/ejhf.2848.","journal-title":"Eur J Heart Fail"},{"key":"2407_CR76","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","volume":"21","author":"C Mueller","year":"2019","unstructured":"Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715\u201331. https:\/\/doi.org\/10.1002\/ejhf.1494.","journal-title":"Eur J Heart Fail"},{"key":"2407_CR77","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"2407_CR78","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cca.2019.05.023","volume":"495","author":"I Pusceddu","year":"2019","unstructured":"Pusceddu I, Dieplinger B, Mueller T. ST2 and the ST2\/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans. Clin Chim Acta. 2019;495:493\u2013500. https:\/\/doi.org\/10.1016\/j.cca.2019.05.023.","journal-title":"Clin Chim Acta"},{"key":"2407_CR79","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.amjcard.2015.01.034","volume":"115","author":"DA Pascual-Figal","year":"2015","unstructured":"Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015;115:B3\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2015.01.034.","journal-title":"Am J Cardiol"},{"key":"2407_CR80","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","volume":"117","author":"S Sanada","year":"2007","unstructured":"Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538\u201349. https:\/\/doi.org\/10.1172\/JCI30634.","journal-title":"J Clin Invest"},{"key":"2407_CR81","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","volume":"74","author":"A Aimo","year":"2019","unstructured":"Aimo A, Januzzi JL Jr., Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, Emdin M. Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74:2193\u2013203. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1039.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR82","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5935\/abc.20150151","volume":"106","author":"H Villacorta","year":"2016","unstructured":"Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016;106:145\u201352. https:\/\/doi.org\/10.5935\/abc.20150151.","journal-title":"Arq Bras Cardiol"},{"key":"2407_CR83","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1593\/tlo.12418","volume":"6","author":"D Bergis","year":"2013","unstructured":"Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH. High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. Transl Oncol. 2013;6:311\u20138. https:\/\/doi.org\/10.1593\/tlo.12418.","journal-title":"Transl Oncol"},{"key":"2407_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-018-1223-3","volume":"36","author":"M Kieler","year":"2018","unstructured":"Kieler M, Unseld M, Wojta J, Kaider A, Bianconi D, Demyanets S, Prager GW. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy. Med Oncol. 2018;36:1. https:\/\/doi.org\/10.1007\/s12032-018-1223-3.","journal-title":"Med Oncol"},{"key":"2407_CR85","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1471-2407-14-198","volume":"14","author":"DP Lu","year":"2014","unstructured":"Lu DP, Zhou XY, Yao LT, Liu CG, Ma W, Jin F, Wu YF. Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer. 2014;14:198. https:\/\/doi.org\/10.1186\/1471-2407-14-198.","journal-title":"BMC Cancer"},{"key":"2407_CR86","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","volume":"75","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Jr. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:1324\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.014.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR87","doi-asserted-by":"publisher","first-page":"e12447","DOI":"10.1097\/MD.0000000000012447","volume":"97","author":"G Huang","year":"2018","unstructured":"Huang G, Zhai J, Huang X, Zheng D. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Med (Baltim). 2018;97:e12447. https:\/\/doi.org\/10.1097\/MD.0000000000012447.","journal-title":"Med (Baltim)"},{"key":"2407_CR88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.breast.2019.12.001","volume":"49","author":"H Aula","year":"2020","unstructured":"Aula H, Skytta T, Tuohinen S, Luukkaala T, Hamalainen M, Virtanen V, Raatikainen P, Moilanen E, Kellokumpu-Lehtinen PL. ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast. 2020;49:183\u20136. https:\/\/doi.org\/10.1016\/j.breast.2019.12.001.","journal-title":"Breast"},{"key":"2407_CR89","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","volume":"5","author":"H Sawaya","year":"2012","unstructured":"Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596\u2013603. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.973321.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2407_CR90","doi-asserted-by":"publisher","unstructured":"Patel SR, Herrmann J, Vierkant RA, Olson JE, Couch FJ, Hazim A, Sloan JA, Loprinzi CL, Ruddy KJ. N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. J Clin Med. 2021;10. https:\/\/doi.org\/10.3390\/jcm10153313.","DOI":"10.3390\/jcm10153313"},{"key":"2407_CR91","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","volume":"135","author":"SL Chow","year":"2017","unstructured":"Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr., Kiernan MS, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017;135:e1054\u201391. https:\/\/doi.org\/10.1161\/CIR.0000000000000490.","journal-title":"Circulation"},{"key":"2407_CR92","doi-asserted-by":"publisher","first-page":"105881","DOI":"10.1016\/j.biocel.2020.105881","volume":"130","author":"RJ Slack","year":"2021","unstructured":"Slack RJ, Mills R, Mackinnon AC. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol. 2021;130:105881. https:\/\/doi.org\/10.1016\/j.biocel.2020.105881.","journal-title":"Int J Biochem Cell Biol"},{"key":"2407_CR93","doi-asserted-by":"publisher","first-page":"131386","DOI":"10.1016\/j.ijcard.2023.131386","volume":"393","author":"IM Seropian","year":"2023","unstructured":"Seropian IM, Fontana Estevez FS, Villaverde A, Cacciagiu L, Bustos R, Touceda V, Penas F, Selser C, Morales C, Miksztowicz V, Gonzalez GE. Galectin-3 contributes to acute cardiac dysfunction and toxicity by increasing oxidative stress and fibrosis in doxorubicin-treated mice. Int J Cardiol. 2023;393:131386. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131386.","journal-title":"Int J Cardiol"},{"key":"2407_CR94","doi-asserted-by":"publisher","unstructured":"Blair BB, Funkhouser AT, Goodwin JL, Strigenz AM, Chaballout BH, Martin JC, Arthur CM, Funk CR, Edenfield WJ, Blenda AV. Increased Circulating Levels of Galectin Proteins in Patients with Breast, Colon, and Lung Cancer. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13194819.","DOI":"10.3390\/cancers13194819"},{"key":"2407_CR95","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1681\/ASN.2014010093","volume":"26","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, Kleber ME, Dressel A, Willmes C, Krane V, et al. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. J Am Soc Nephrol. 2015;26:2213\u201321. https:\/\/doi.org\/10.1681\/ASN.2014010093.","journal-title":"J Am Soc Nephrol"},{"key":"2407_CR96","doi-asserted-by":"publisher","first-page":"120777","DOI":"10.1016\/j.cca.2025.120777","volume":"581","author":"AA Bhat","year":"2026","unstructured":"Bhat AA, Alghazwani Y, Chidambaram K, Rekha MM, Sahoo S, Goud P, Sayyed N, Jakhmola V, Shahwan M, Kazmi I, et al. Galectin-3 as a cardiac biomarker. Clin Chim Acta. 2026;581:120777. https:\/\/doi.org\/10.1016\/j.cca.2025.120777.","journal-title":"Clin Chim Acta"},{"key":"2407_CR97","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1016\/j.jacc.2018.09.076","volume":"72","author":"A Ghorbani","year":"2018","unstructured":"Ghorbani A, Bhambhani V, Christenson RH, Meijers WC, de Boer RA, Levy D, Larson MG, Ho JE. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. J Am Coll Cardiol. 2018;72:3246\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.076.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR98","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr., Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.061.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR99","doi-asserted-by":"publisher","unstructured":"Wu Y, Gao D, Xue J, Zuo Z. Galectin-3 and Myeloperoxidase May Monitor Cancer-Therapy-Related Cardiotoxicity? A Systematic Review and Meta-Analysis. Biomolecules. 2022;12. https:\/\/doi.org\/10.3390\/biom12121788.","DOI":"10.3390\/biom12121788"},{"key":"2407_CR100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.abb.2018.01.004","volume":"640","author":"Y Aratani","year":"2018","unstructured":"Aratani Y, Myeloperoxidase. Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018;640:47\u201352. https:\/\/doi.org\/10.1016\/j.abb.2018.01.004.","journal-title":"Arch Biochem Biophys"},{"key":"2407_CR101","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cca.2019.02.022","volume":"493","author":"G Ndrepepa","year":"2019","unstructured":"Ndrepepa G. Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta. 2019;493:36\u201351. https:\/\/doi.org\/10.1016\/j.cca.2019.02.022.","journal-title":"Clin Chim Acta"},{"key":"2407_CR102","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.freeradbiomed.2021.04.021","volume":"169","author":"U Attanasio","year":"2021","unstructured":"Attanasio U, Pirozzi F, Poto R, Cuomo A, Carannante A, Russo M, Ghigo A, Hirsch E, Tocchetti CG, Varricchi G, Mercurio V. Oxidative stress in anticancer therapies-related cardiac dysfunction. Free Radic Biol Med. 2021;169:410\u20135. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.04.021.","journal-title":"Free Radic Biol Med"},{"key":"2407_CR103","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","volume":"61","author":"M Putt","year":"2015","unstructured":"Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, et al. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015;61:1164\u201372. https:\/\/doi.org\/10.1373\/clinchem.2015.241232.","journal-title":"Clin Chem"},{"key":"2407_CR104","doi-asserted-by":"publisher","first-page":"e014708","DOI":"10.1161\/JAHA.119.014708","volume":"9","author":"BG Demissei","year":"2020","unstructured":"Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, et al. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J Am Heart Assoc. 2020;9:e014708. https:\/\/doi.org\/10.1161\/JAHA.119.014708.","journal-title":"J Am Heart Assoc"},{"key":"2407_CR105","doi-asserted-by":"publisher","first-page":"214","DOI":"10.18632\/oncotarget.28182","volume":"13","author":"MRB Wanderley Jr","year":"2022","unstructured":"Wanderley MRB Jr., Avila MS, Fernandes-Silva MM, Cruz FDD, Brandao SMG, Rigaud VOC, Hajjar LA, Filho RK, Cunha-Neto E, Bocchi EA, Ayub-Ferreira SM. Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECCY Trial. Oncotarget. 2022;13:214\u201323. https:\/\/doi.org\/10.18632\/oncotarget.28182.","journal-title":"Oncotarget"},{"key":"2407_CR106","doi-asserted-by":"publisher","first-page":"107711","DOI":"10.1016\/j.pharmthera.2020.107711","volume":"221","author":"SL Maiocchi","year":"2021","unstructured":"Maiocchi SL, Ku J, Thai T, Chan E, Rees MD, Thomas SR. Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease. Pharmacol Ther. 2021;221:107711. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107711.","journal-title":"Pharmacol Ther"},{"key":"2407_CR107","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1089\/ars.2019.7971","volume":"32","author":"CJA Ramachandra","year":"2020","unstructured":"Ramachandra CJA, Ja K, Chua J, Cong S, Shim W, Hausenloy DJ. Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection. Antioxid Redox Signal. 2020;32:1135\u201349. https:\/\/doi.org\/10.1089\/ars.2019.7971.","journal-title":"Antioxid Redox Signal"},{"key":"2407_CR108","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","volume":"13","author":"K Ananthan","year":"2020","unstructured":"Ananthan K, Lyon AR. The Role of Biomarkers in Cardio-Oncology. J Cardiovasc Transl Res. 2020;13:431\u201350. https:\/\/doi.org\/10.1007\/s12265-020-10042-3.","journal-title":"J Cardiovasc Transl Res"},{"key":"2407_CR109","doi-asserted-by":"publisher","unstructured":"Datta S, Koka S, Boini KM. Understanding the Role of Adipokines in Cardiometabolic Dysfunction: A Review of Current Knowledge. Biomolecules. 2025;15. https:\/\/doi.org\/10.3390\/biom15050612.","DOI":"10.3390\/biom15050612"},{"key":"2407_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20030407","volume":"374","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1\u201320. https:\/\/doi.org\/10.1042\/BJ20030407.","journal-title":"Biochem J"},{"key":"2407_CR111","doi-asserted-by":"publisher","unstructured":"Attanasio U, Di Sarro E, Tricarico L, Di Lisi D, Armentaro G, Miceli S, Fioretti F, Deidda M, Correale M, Novo G, et al. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond. Biomolecules. 2024;14. https:\/\/doi.org\/10.3390\/biom14020199.","DOI":"10.3390\/biom14020199"},{"key":"2407_CR112","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/jnci\/djr216","volume":"103","author":"SR Pine","year":"2011","unstructured":"Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso NE, Harris CC. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103:1112\u201322. https:\/\/doi.org\/10.1093\/jnci\/djr216.","journal-title":"J Natl Cancer Inst"},{"key":"2407_CR113","doi-asserted-by":"publisher","unstructured":"Borowiec A, Ozdowska P, Rosinska M, Zebrowska AM, Jasek S, Kotowicz B, Makowka A, Waniewska J, Kosela-Paterczyk H, Lampka E, et al. Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha. Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms26094071.","DOI":"10.3390\/ijms26094071"},{"key":"2407_CR114","doi-asserted-by":"publisher","first-page":"1232269","DOI":"10.3389\/fcvm.2024.1232269","volume":"11","author":"V Quagliariello","year":"2024","unstructured":"Quagliariello V, Passariello M, Bisceglia I, Paccone A, Inno A, Maurea C, Rapuano Lembo R, Manna L, Iovine M, Canale ML, et al. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1beta and interleukin-6: biochemical implications in cardio-immuno-oncology. Front Cardiovasc Med. 2024;11:1232269. https:\/\/doi.org\/10.3389\/fcvm.2024.1232269.","journal-title":"Front Cardiovasc Med"},{"key":"2407_CR115","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-012-2039-z","volume":"134","author":"AA Onitilo","year":"2012","unstructured":"Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012;134:291\u20138. https:\/\/doi.org\/10.1007\/s10549-012-2039-z.","journal-title":"Breast Cancer Res Treat"},{"key":"2407_CR116","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"2407_CR117","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12885-025-13583-5","volume":"25","author":"M Getie","year":"2025","unstructured":"Getie M, Mekonnen BA, Seifu D, Mulugeta Y, Tebeje S, Tafere C, Amuamuta A. Serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with breast cancer attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. BMC Cancer. 2025;25:175. https:\/\/doi.org\/10.1186\/s12885-025-13583-5.","journal-title":"BMC Cancer"},{"key":"2407_CR118","doi-asserted-by":"publisher","unstructured":"Ali A, Caldwell R, Pina G, Beinart N, Jensen G, Yusuf SW, Koutroumpakis E, Hamzeh I, Khalaf S, Iliescu C, et al. Elevated IL-6 and Tumor Necrosis Factor-alpha in Immune Checkpoint Inhibitor Myocarditis. Diseases. 2024;12. https:\/\/doi.org\/10.3390\/diseases12050088.","DOI":"10.3390\/diseases12050088"},{"key":"2407_CR119","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti TNFTACHFI. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133\u201340. https:\/\/doi.org\/10.1161\/01.CIR.0000077913.60364.D2.","journal-title":"Circulation"},{"key":"2407_CR120","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/10408363.2019.1678565","volume":"57","author":"M Arkoumani","year":"2020","unstructured":"Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC, Kanaka-Gantenbein C, Tentolouris N, Papassotiriou I. The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update. Crit Rev Clin Lab Sci. 2020;57:114\u201325. https:\/\/doi.org\/10.1080\/10408363.2019.1678565.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2407_CR121","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","volume":"63","author":"KC Wollert","year":"2017","unstructured":"Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017;63:140\u201351. https:\/\/doi.org\/10.1373\/clinchem.2016.255174.","journal-title":"Clin Chem"},{"key":"2407_CR122","doi-asserted-by":"publisher","first-page":"120839","DOI":"10.1016\/j.cca.2026.120839","volume":"583","author":"O Afzal","year":"2026","unstructured":"Afzal O, Afzal M, Khan NH, Altharawi A, Alamri MA, Alossaimi MA, Altamimi ASA, Goud P. GDF-15 as an integrative cardiometabolic biomarker. Clin Chim Acta. 2026;583:120839. https:\/\/doi.org\/10.1016\/j.cca.2026.120839.","journal-title":"Clin Chim Acta"},{"key":"2407_CR123","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jchf.2017.07.013","volume":"5","author":"A Sharma","year":"2017","unstructured":"Sharma A, Stevens SR, Lucas J, Fiuzat M, Adams KF, Whellan DJ, Donahue MP, Kitzman DW, Pi\u00f1a IL, Zannad F, et al. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. JACC Heart Fail. 2017;5:724\u201334. https:\/\/doi.org\/10.1016\/j.jchf.2017.07.013.","journal-title":"JACC Heart Fail"},{"key":"2407_CR124","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/circulationaha.109.928846","volume":"122","author":"IS Anand","year":"2010","unstructured":"Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122:1387\u201395. https:\/\/doi.org\/10.1161\/circulationaha.109.928846.","journal-title":"Circulation"},{"key":"2407_CR125","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.amjcard.2013.05.013","volume":"112","author":"DJ Lok","year":"2013","unstructured":"Lok DJ, Klip IT, Lok SI, de la Bruggink-Andr\u00e9 PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol. 2013;112:831\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2013.05.013.","journal-title":"Am J Cardiol"},{"key":"2407_CR126","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaccao.2023.12.009","volume":"6","author":"HM Boen","year":"2024","unstructured":"Boen HM, Cherubin M, Franssen C, Gevaert AB, Witvrouwen I, Bosman M, Guns PJ, Heidbuchel H, Loeys B, Alaerts M, Van Craenenbroeck EM. Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024;6:183\u201399. https:\/\/doi.org\/10.1016\/j.jaccao.2023.12.009.","journal-title":"JACC CardioOncol"},{"key":"2407_CR127","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3892\/ol.2021.12821","volume":"22","author":"Y Chen","year":"2021","unstructured":"Chen Y, Xu Y, Deng Z, Wang Y, Zheng Y, Jiang W, Jiang L. MicroRNA expression profiling involved in doxorubicin-induced cardiotoxicity using high-throughput deep-sequencing analysis. Oncol Lett. 2021;22:560. https:\/\/doi.org\/10.3892\/ol.2021.12821.","journal-title":"Oncol Lett"},{"key":"2407_CR128","doi-asserted-by":"publisher","first-page":"1055911","DOI":"10.3389\/fphar.2022.1055911","volume":"13","author":"I Kawano","year":"2022","unstructured":"Kawano I, Adamcova M. MicroRNAs in doxorubicin-induced cardiotoxicity: The DNA damage response. Front Pharmacol. 2022;13:1055911. https:\/\/doi.org\/10.3389\/fphar.2022.1055911.","journal-title":"Front Pharmacol"},{"key":"2407_CR129","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.18632\/oncotarget.14355","volume":"8","author":"VO Rigaud","year":"2017","unstructured":"Rigaud VO, Ferreira LR, Ayub-Ferreira SM, Avila MS, Brandao SM, Cruz FD, Santos MH, Cruz CB, Alves MS, Issa VS, et al. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget. 2017;8:6994\u20137002. https:\/\/doi.org\/10.18632\/oncotarget.14355.","journal-title":"Oncotarget"},{"key":"2407_CR130","doi-asserted-by":"publisher","unstructured":"Leger KJ, Leonard D, Nielson D, de Lemos JA, Mammen PP, Winick NJ. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy. J Am Heart Assoc. 2017;6. https:\/\/doi.org\/10.1161\/JAHA.116.004653.","DOI":"10.1161\/JAHA.116.004653"},{"key":"2407_CR131","doi-asserted-by":"publisher","unstructured":"Anastasiou M, Oikonomou E, Theofilis P, Gazouli M, Papamikroulis GA, Goliopoulou A, Tsigkou V, Skandami V, Margoni A, Cholidou K, et al. MicroRNA Signatures and Machine Learning Models for Predicting Cardiotoxicity in HER2-Positive Breast Cancer Patients. Pharmaceuticals (Basel). 2025;18. https:\/\/doi.org\/10.3390\/ph18121908.","DOI":"10.3390\/ph18121908"},{"key":"2407_CR132","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1113\/JP278131","volume":"598","author":"FP Kreutzer","year":"2020","unstructured":"Kreutzer FP, Fiedler J, Thum T. Non-coding RNAs: key players in cardiac disease. J Physiol. 2020;598:2995\u20133003. https:\/\/doi.org\/10.1113\/JP278131.","journal-title":"J Physiol"},{"key":"2407_CR133","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41401-020-0471-x","volume":"42","author":"HG Fa","year":"2021","unstructured":"Fa HG, Chang WG, Zhang XJ, Xiao DD, Wang JX. Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets. Acta Pharmacol Sin. 2021;42:499\u2013507. https:\/\/doi.org\/10.1038\/s41401-020-0471-x.","journal-title":"Acta Pharmacol Sin"},{"key":"2407_CR134","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaccao.2024.10.004","volume":"7","author":"S Poudel","year":"2025","unstructured":"Poudel S, Shrestha H, Pan Y, Li Q, Li K, Im C, Dixon SB, Ehrhardt MJ, Mulrooney DA, Zhou S, et al. Serum Proteins Predict Treatment-Related Cardiomyopathy Among Survivors of Childhood Cancer. JACC CardioOncol. 2025;7:56\u201367. https:\/\/doi.org\/10.1016\/j.jaccao.2024.10.004.","journal-title":"JACC CardioOncol"},{"key":"2407_CR135","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11306-025-02258-8","volume":"21","author":"A Singh","year":"2025","unstructured":"Singh A, Bakhtyar M, Jun SR, Boerma M, Lan RS, Su LJ, Makhoul S, Hsu PC. A narrative review of metabolomics approaches in identifying biomarkers of doxorubicin-induced cardiotoxicity. Metabolomics. 2025;21:68. https:\/\/doi.org\/10.1007\/s11306-025-02258-8.","journal-title":"Metabolomics"},{"key":"2407_CR136","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","volume":"140","author":"P Garcia-Pavia","year":"2019","unstructured":"Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, Toepfer CN, Getz K, Gorham J, Patel P, et al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019;140:31\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037934.","journal-title":"Circulation"},{"key":"2407_CR137","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2025.02.007","volume":"111","author":"N Zhang","year":"2025","unstructured":"Zhang N, Tian X, Sun D, Tse G, Xie B, Zhao Z, Liu T. Clonal hematopoiesis, cardiovascular disease and cancer treatment-induced cardiotoxicity. Semin Cancer Biol. 2025;111:89\u2013114. https:\/\/doi.org\/10.1016\/j.semcancer.2025.02.007.","journal-title":"Semin Cancer Biol"},{"key":"2407_CR138","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1001\/jamaoncol.2025.5785","volume":"12","author":"D Shyr","year":"2026","unstructured":"Shyr D, Pershad Y, Zhao K, Kishtagari A, Corty RW, Shinohara E, Park BH, Heimlich JB, Luo L, Bick AG. Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid Tumors. JAMA Oncol. 2026;12:251\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2025.5785.","journal-title":"JAMA Oncol"},{"key":"2407_CR139","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.0455","author":"CS Park","year":"2026","unstructured":"Park CS, Ryu G, Ahn HJ, Sun C, Lee SP, Kim HK, Kim YJ, Jeon SY, Lee HB, Moon HG, et al. Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects. JAMA Oncol. 2026. https:\/\/doi.org\/10.1001\/jamaoncol.2026.0455.","journal-title":"JAMA Oncol"},{"key":"2407_CR140","doi-asserted-by":"publisher","first-page":"e940","DOI":"10.1161\/CIR.0000000000001404","volume":"153","author":"JW Rhee","year":"2026","unstructured":"Rhee JW, Bolton KL, Gupta D, Weeks LD, Bick AG, Tall AR, Walsh K, Fuster JJ, Natarajan P, American Heart Association Molecular Determinants of Cardiovascular Health Committee of the Council on G. Clonal Hematopoiesis and Its Cardiovascular Implications: A Scientific Statement From the American Heart Association. Circulation. 2026;153:e940\u201352. https:\/\/doi.org\/10.1161\/CIR.0000000000001404.","journal-title":"Circulation"},{"key":"2407_CR141","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1161\/CIR.0000000000001354","volume":"152","author":"CG Mihos","year":"2025","unstructured":"Mihos CG, Liu JE, Anderson KM, Pernetz MA, O\u2019Driscoll JM, Aurigemma GP, Ujueta F, Wessly P, American Heart Association Council on Peripheral Vascular D, Council on C. Speckle-Tracking Strain Echocardiography for the Assessment of Left Ventricular Structure and Function: A Scientific Statement From the American Heart Association. Circulation. 2025;152:e96\u2013109. https:\/\/doi.org\/10.1161\/CIR.0000000000001354.","journal-title":"Circulation"},{"key":"2407_CR142","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.echo.2025.07.007","volume":"38","author":"JD Thomas","year":"2025","unstructured":"Thomas JD, Edvardsen T, Abraham T, Appadurai V, Badano L, Banchs J, Cho GY, Cosyns B, Delgado V, Donal E, et al. Clinical Applications of Strain Echocardiography: A Clinical Consensus Statement From the American Society of Echocardiography Developed in Collaboration With the European Association of Cardiovascular Imaging of the European Society of Cardiology. J Am Soc Echocardiogr. 2025;38:985\u20131020. https:\/\/doi.org\/10.1016\/j.echo.2025.07.007.","journal-title":"J Am Soc Echocardiogr"},{"key":"2407_CR143","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","volume":"80","author":"LA Baldassarre","year":"2022","unstructured":"Baldassarre LA, Ganatra S, Lopez-Mattei J, Yang EH, Zaha VG, Wong TC, Ayoub C, DeCara JM, Dent S, Deswal A, et al. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;80:1560\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.743.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR144","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiol. 2019;4:1007\u201318. https:\/\/doi.org\/10.1001\/jamacardio.2019.2952.","journal-title":"JAMA Cardiol"},{"key":"2407_CR145","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, Aakhus S, Miyazaki S, Shirazi M, Galderisi M, et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021;77:392\u2013401. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.020.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR146","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","volume":"45","author":"TH Marwick","year":"2024","unstructured":"Marwick TH, Dewar E, Nolan M, Shirazi M, Dias P, Wright L, Fitzgerald B, Kearney L, Srivastava P, Atherton J, et al. Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J. 2024;45:4414\u201324. https:\/\/doi.org\/10.1093\/eurheartj\/ehae574.","journal-title":"Eur Heart J"},{"key":"2407_CR147","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","volume":"148","author":"D Addison","year":"2023","unstructured":"Addison D, Neilan TG, Barac A, Scherrer-Crosbie M, Okwuosa TM, Plana JC, Reding KW, Taqueti VR, Yang EH, Zaha VG, et al. Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation. 2023;148:1271\u201386. https:\/\/doi.org\/10.1161\/CIR.0000000000001174.","journal-title":"Circulation"},{"key":"2407_CR148","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","volume":"11","author":"JC Plana","year":"2018","unstructured":"Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient. JACC Cardiovasc Imaging. 2018;11:1173\u201386. https:\/\/doi.org\/10.1016\/j.jcmg.2018.06.003.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2407_CR149","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, Awadalla M, Nohria A, Zlotoff DA, Thuny F, et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol. 2021;77:1503\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.050.","journal-title":"J Am Coll Cardiol"},{"key":"2407_CR150","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamacardio.2023.0494","volume":"8","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Shalmon T, Fan CS, Houbois C, Amir E, Thevakumaran Y, Somerset E, Malowany JM, Urzua-Fresno C, Yip P, et al. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer. JAMA Cardiol. 2023;8:524\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2023.0494.","journal-title":"JAMA Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02407-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:46:49Z","timestamp":1788508009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02407-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2407"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02407-y","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No animal or human subjects were used by the authors in this study.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alvin Chandra reports grants from Novo Nordisk, Tenax, and Sarfez, outside the submitted work. The other authors have nothing to disclose.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}